Abstract:Dear Editor: In a recent issue of the Journal of Surgical Oncology, Huh et al. [1] evaluated the prognostic value of the preoperative serum carcinoembryonic antigen (CEA) level in patients with colon cancer. The authors concluded that preoperative serum CEA is a reliable predictor of recurrence and survival after curative surgery in patients with colon cancer. Colorectal cancer is one of the leading causes of cancer death in the Western world [2]. Even among patients who undergo potentially curative resection alone, 40–50% of them ultimately relapse and die of metastatic disease [3]. Although the TNM stage, which is determined by the depth of invasion, the involvement of the lymph nodes and distant metastasis, remains the most significant independent prognostic indicator in patients with colon cancer, the prognosis of patients within the same stage may vary considerably depending on the intrinsic biologic characteristics of the individual tumor, indicating that the conventional staging procedures may be unable to precisely predict cancer prognosis. It is essential to predict precisely the risk of recurrence and metastases in order to minimize adverse effects and to maximize the therapeutic effect in the treatment of cancer patients. Also, additional prognostic indicators for patient differentiation to individualize adjuvant or neoadjuvant treatment are needed. The advances in molecular biology have transformed clinical oncology with respect to the prevention, diagnosis and treatment of cancer. Oncogenes and tumor-suppressor genes, growth factors and their corresponding receptors, adhesion molecules and angiogenic molecules have been studied in relation to tumorgenesis, growth, invasion, and metastases. In this regard, many studies are directed towards the development of new prognostic factors with these molecular markers to appropriately select patients for adjuvant systemic or targeted therapies. CEA is one of the most widely used tumor markers worldwide [4]. The majority of studies suggest that CEA level can provide prognostic data in patients with colorectal cancer. CEA may thus be able to help identify the subset of patients with aggressive disease who might benefit from adjuvant chemotherapy [5]. However, it is important to point out that currently there are no reports showing a benefit from the use of adjuvant therapy based solely on an increased preoperative CEA concentration. The clinical value of CEA in colon cancer is still not fully understood. Obviously, other markers or combinations of markers that better predict response to a chosen treatment are urgently needed. For a new prognostic factor to be clinically useful in colon cancer it should provide information that is independent of existing staging systems, be a stronger indicator of prognosis than the existing systems, or provide prognostic information within the subgroups of the existing systems. More data will be needed to incorporate novel markers into clinical practice. It is likely that we will see more and more biomarkers come into clinical practice to direct individualized treatment. Over the past decade, we have witnessed an important development in the field of colon cancer treatment [6]. Targeted therapy is targeted to specific pathways involved in tumor growth, progression, and metastases. This target-based approach is adding to the treatment options for cancer, and these treatments should be less toxic to normal cells and thus improve the therapeutic efficacy. For most solid tumors, although they may appear to be morphologically similar on microscopic examination, molecular studies can identify different genetic alterations in tumors from different patients. Due to this heterogeneity, an agent targeting one particular pathway is unlikely to be effective in all patients. Clearly, there is a need to identify those patients who are most likely to respond to a specific therapy. Individualized therapies that are tailored to a patient’s genetic composition and tests that can predict which therapy patient will respond to will be of tremendous value for the treatment of colon cancer. Despite significant progress in the development of new therapies over the last decade, colon cancer remains one of the top three causes of cancer death in the United States. Many of these patients will receive one or more lines of chemotherapy, but not everyone responds to each regimen. Development of robust biomarkers for recurrence or metastases risk stratification and response prediction has proved to be very difficult. Given the poor prognosis of patients with colorectal cancer despite appropriate surgery and chemoradiation treatment, rational research efforts are ongoing to discover novel markers toward survival prediction and target treatment, and develop robust markers for patient-tailored treatment [7]. The recent revolution in personal genomics provides exciting findings for the discovery of novel genetic variants and risk alleles [8]. Current advances in the identification of human genetic variation, namely single-nucleotide polymorphisms and copy-number variations that might be responsible for differences in local recurrence risk and metastases among patients with colorectal cancer, might be useful in a clinical setting [9]. Prospects for the future arise from new research based on genetics, epigenetics, geneexpression profiling studies toward development of biomarkers to guide personalized approaches to primary prevention-targeted screening of the population and to treat colon cancer.

Clinical research on detecting multimarker genera in peripheral blood of patients with colorectal carcinoma and its clinical significance

Expression and significance of miR-654-5p and miR-376b-3p in patients with colon cancer

Quantitative Real-Time RT-PCR Detection for CEA, CK20 and CK19 Mrna in Peripheral Blood of Colorectal Cancer Patients.

Circulating Tumor DNA As a Promising Biomarker of Relapse Risk for Stage II-III Colorectal Cancer.

[Relationship Between the Protein Expression of P53, C-Erbb-2, Vascular Endothelial Growth Factor and CD44 and the Survival Rates of Stage II( Colorectal Cancer Patients Without Radiochemotherapy after Radical Resection].

Dissemination Profile of Perioperative Tumor Cells in Peripheral Blood of Colorectal Cancer Patients Detected by Multiple Marker Genes

Multipoint Quantification of Multimarker Genes in Peripheral Blood and Micrometastasis Characteristic in Peri-Operative Esophageal Cancer Patients

Clinical Significance of Combined Diagnostic Tests of Serum Markers in Detecting Metastasis Colorectal Cancer

Combination Detection of Three Gene Markers Expressed in Circulating Cancer Cells of Non-Small Cell Lung Cancer

Quantitative detection of CEA level in the peritoneal cavity of colorectal carcinoma patients with real-time RT-PCR and Its clinical significance

Significance of CK20 Mrna Expression in Peripheral Blood of Colorectal Cancer Patients by Real-Time Fluorescent Quantitative RT-PCR

[Detection and Clinical Significance of Circulating Tumor Cells in Patients with Colorectal Carcinoma].

An Urgent Need To Develop Novel Markers For Prognosis In Colon Cancer

Use of Peripheral Blood Mrna Signatures to Distinguish Colorectal Cancer Patients from Colonoscopy-Negative Patients

Clinical Usefulness of Serum Tumor markers CEA, CA19-9 and CA72-4 in Colorectal Cancer Diagnosis

Quantitative Detection of Disseminated Cancer Cells in Peritoneal Washes with Real-Time RT-PCR for Patients with Colorectal Carcinoma and Its Clinical Significance

[Significance of Combined Determination of CK19mRNA, Carcinoembryanic Antigen, Neuron-Specific Enolase, and Tissue Polypeptide Antigen in Peripheral Blood of Patients with Lung Cancer].

Expression and clinical significance of Survivin and CyclinD1 in colorectal carcinoma

Peripheral blood mRNA signature for colorectal cancer screening.

Clinical Significance of a Novel Tumor Progression-Associated Immune Signature in Colorectal Adenocarcinoma

[Prognostic value of combining preoperative serum tumor markers and peripheral blood routine indexes in patients with colorectal cancer].